Dian Diagnostics GroupLtd (SZSE:300244) Stock Valuation, Peer Comparison & Price Targets

Q: What is the Fair Price of 300244 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

300244 (CN¥12.7) is trading below our estimate of [[fair value]] (CN¥36.73)

Share Price vs Fair Value

What is the Fair Price of 300244 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300244 (CN¥12.7) is trading below our estimate of fair value (CN¥36.73)

Significantly Below Fair Value: 300244 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300244?

Key metric: As 300244 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 300244. This is calculated by dividing 300244's market cap by their current revenue.
What is 300244's PS Ratio?
PS Ratio	0.6x
Sales	CN¥12.37b
Market Cap	CN¥7.77b

300244 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	17.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 300244's PS Ratio compare to its peers?

The above table shows the PS ratio for 300244 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.6x
600682 Nanjing Xinjiekou Department Store	1.4x	9.4%	CN¥9.6b
300962 Zhongjin Irradiation	12x	n/a	CN¥4.3b
603882 Guangzhou Kingmed Diagnostics Group	1.9x	10.4%	CN¥14.7b
301103 Liaoning He Eye Hospital Group	3.1x	n/a	CN¥3.5b
300244 Dian Diagnostics GroupLtd	0.6x	8.2%	CN¥7.8b

Price-To-Sales vs Peers: 300244 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (4.6x).

Price to Sales Ratio vs Industry

How does 300244's PS Ratio compare vs other companies in the CN Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
601607 Shanghai Pharmaceuticals Holding	0.3x	9.5%	US$9.88b
600998 Jointown Pharmaceutical Group	0.2x	8.0%	US$3.53b
000028 China National Accord Medicines	0.2x	5.7%	US$2.10b
000950 C.Q. Pharmaceutical Holding	0.1x	10.1%	US$1.33b

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 300244 is good value based on its Price-To-Sales Ratio (0.6x) compared to the CN Healthcare industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is 300244's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300244 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.6x
Fair PS Ratio	1.2x

Price-To-Sales vs Fair Ratio: 300244 is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300244 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥12.70	CN¥11.94 -6.0%	18.8%	CN¥14.00	CN¥8.37	n/a	7
Nov ’25	CN¥12.31	CN¥11.71 -4.9%	19.0%	CN¥14.00	CN¥8.37	n/a	7
Oct ’25	CN¥13.65	CN¥12.57 -7.9%	18.5%	CN¥16.00	CN¥8.50	n/a	7
Sep ’25	CN¥10.53	CN¥12.90 +22.5%	16.8%	CN¥15.00	CN¥8.50	n/a	7
Aug ’25	CN¥12.49	CN¥16.15 +29.3%	19.4%	CN¥20.00	CN¥10.00	n/a	7
Jul ’25	CN¥11.90	CN¥22.37 +87.9%	36.5%	CN¥40.00	CN¥15.25	n/a	7
Jun ’25	CN¥13.38	CN¥22.37 +67.2%	36.5%	CN¥40.00	CN¥15.25	n/a	7
May ’25	CN¥14.10	CN¥27.31 +93.7%	24.6%	CN¥40.00	CN¥18.50	n/a	8
Apr ’25	CN¥18.14	CN¥29.08 +60.3%	17.0%	CN¥40.00	CN¥22.48	n/a	8
Mar ’25	CN¥19.25	CN¥29.67 +54.1%	16.9%	CN¥40.00	CN¥22.48	n/a	7
Feb ’25	CN¥17.42	CN¥30.84 +77.0%	13.2%	CN¥40.00	CN¥27.00	n/a	7
Jan ’25	CN¥23.81	CN¥31.13 +30.7%	12.4%	CN¥40.00	CN¥27.98	n/a	7
Dec ’24	CN¥26.58	CN¥31.13 +17.1%	12.4%	CN¥40.00	CN¥27.98	n/a	7
Nov ’24	CN¥22.76	CN¥33.71 +48.1%	16.0%	CN¥43.04	CN¥28.00	CN¥12.31	7
Oct ’24	CN¥23.50	CN¥35.02 +49.0%	14.3%	CN¥43.04	CN¥29.00	CN¥13.65	7
Sep ’24	CN¥22.67	CN¥36.45 +60.8%	15.0%	CN¥45.00	CN¥29.00	CN¥10.53	7
Aug ’24	CN¥23.87	CN¥37.77 +58.3%	11.4%	CN¥45.00	CN¥32.00	CN¥12.49	7
Jul ’24	CN¥25.63	CN¥37.77 +47.4%	11.4%	CN¥45.00	CN¥32.00	CN¥11.90	7
Jun ’24	CN¥25.50	CN¥37.77 +48.1%	11.4%	CN¥45.00	CN¥32.00	CN¥13.38	7
May ’24	CN¥27.08	CN¥40.58 +49.8%	22.6%	CN¥60.00	CN¥32.00	CN¥14.10	7
Apr ’24	CN¥28.65	CN¥42.62 +48.8%	22.1%	CN¥60.00	CN¥32.00	CN¥18.14	6
Mar ’24	CN¥26.49	CN¥42.62 +60.9%	22.1%	CN¥60.00	CN¥32.00	CN¥19.25	6
Feb ’24	CN¥27.27	CN¥43.12 +58.1%	21.0%	CN¥60.00	CN¥32.00	CN¥17.42	6
Jan ’24	CN¥25.13	CN¥45.12 +79.5%	16.4%	CN¥60.00	CN¥38.00	CN¥23.81	6
Dec ’23	CN¥27.47	CN¥45.79 +66.7%	15.2%	CN¥60.00	CN¥38.00	CN¥26.58	6
Nov ’23	CN¥28.59	CN¥45.80 +60.2%	15.2%	CN¥60.00	CN¥38.00	CN¥22.76	6

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.77

7D

-3.4%

1Y

-34.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

7D

5.4%

1Y

-14.7%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.72

7D

2.3%

1Y

36.8%

Dian Diagnostics GroupLtd Valuation